UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact over standard of care.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

The study included 29 eyes of 28 patients receiving intravitreal 2 mg/0.05 ml aflibercept injection for the treatment of wet AMD resistant to intravitreal ranibizumab injections. There were 11 ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks. Patients in both ...

Per FDA guidance, all patients will receive three loading doses of aflibercept prior to receiving Ixo-vec. Patients in both arms will be eligible for supplemental injections of aflibercept and ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...